Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.

and evidence of atherosclerotic cardiovascular disease (ASCVD). The main objective of the study was to show a durability of response, which has been achieved, allowing Amgen to press ahead with ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

At the heart of the dispute is whether Amgen's claims are ... court's view that companies that prove the commercial viability of products should not be penalized by small and inconclusive clinical ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA ... Executive Medical Director, Amgen UK & Ireland ...

Tapotoclax is under clinical development by Amgen and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular ... next-generation products, Aranesp and ...